A Multi-Center, Open-Label, Follow-up Study to Assess the Long-Term Safety of 125 mg Per Day of Oral Azimilide Dihydrochloride in Patients With an Implantable Cardioverter Defibrillator.
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2017
At a glance
- Drugs Azimilide (Primary)
- Indications Arrhythmias
- Focus Adverse reactions; Registrational
- Sponsors Procter & Gamble
- 27 Sep 2008 New trial record.